uniQure to Announce Third Quarter 2025 Financial Results
Rhea-AI Summary
uniQure (NASDAQ: QURE) will report third quarter 2025 financial results before market open on Monday, November 10, 2025. Management will host a conference call at 8:30 a.m. ET the same day that will be webcast under the Events & Presentations section of uniQure’s investor website.
Analysts may join the live Q&A by dialing (646) 307-1963 or toll-free (800) 715-9871 with passcode 2196195. Attendees are asked to join 15 minutes before the start time. A replay of the webcast will be archived for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction 34 Alerts
On the day this news was published, QURE gained 5.56%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.5% during that session. Argus tracked a trough of -6.6% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $96M to the company's valuation, bringing the market cap to $1.83B at that time.
Data tracked by StockTitan Argus on the day of publication.
~ uniQure to host earnings call on Monday, November 10, 2025 at 8:30 a.m. ET ~
LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report third quarter 2025 financial results before market open on Monday, November 10, 2025. Management will then host a conference call at 8:30 a.m. ET.
The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering the passcode 2196195. If you are joining the conference call, please join 15 minutes before the start time.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com
| uniQure Contacts: | |
| FOR INVESTORS: | FOR MEDIA: |
| Chiara Russo | Tom Malone |
| Direct: 781-491-4371 | Direct: 339-970-7558 |
| Mobile: 617-306-9137 | Mobile:339-223-8541 |
| c.russo@uniQure.com | t.malone@uniQure.com |
FAQ
When will uniQure (QURE) release its third quarter 2025 financial results?
What time is the uniQure (QURE) earnings call on November 10, 2025?
How can investors access the uniQure (QURE) live webcast for the Q3 2025 call?
What dial‑in should analysts use to join the uniQure (QURE) Q3 2025 conference call?
Will a replay of uniQure (QURE) Q3 2025 earnings be available after the call?
When should I join the uniQure (QURE) conference call on November 10, 2025?
